{"product_id":"sybx-vrio-analysis","title":"Synlogic, Inc. (SYBX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Synlogic, Inc. (SYBX) truly built to last? This VRIO analysis cuts straight to the core of its competitive edge, dissecting its Value, Rarity, Inimitability, and Organization to reveal whether its current strengths are fleeting advantages or sustainable dominance in the market. Discover the critical factors underpinning (or undermining) its long-term success - dive into the full breakdown below to see the definitive verdict.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e1. Synthetic Biotic Platform Technology\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a core technology that defines Synlogic, Inc. (SYBX) in the crowded biotech space. This platform is their engine, designed to create oral, gut-localized medicines programmed to manage diseases by consuming or producing specific metabolites right where they are needed. This focus on GI-restricted action is key to their strategy.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Novel, Localized Therapeutic Action\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is clear: creating medicines that act locally in the gut, avoiding systemic exposure, which can lower side effects and target diseases with validated metabolite pathways. This platform is fueling their entire clinical effort. For instance, their lead candidate, labafenogene marselecobac (SYNB1934), is in a global, pivotal Phase III study for phenylketonuria (PKU). Also in the pipeline are SYNB1353 for homocystinuria (HCU) in Phase I, and SYNB8802 for enteric hyperoxaluria in Phase II. The broader synthetic biology technology in healthcare market is projected to reach USD 5.15 billion in 2025, showing the recognized value in this scientific domain.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Precision Engineering on Probiotics\u003c\/h3\u003e\n\u003cp\u003eWhat makes this approach rare is the specific combination: taking well-characterized probiotics and applying precision genetic engineering to program them for in vivo (in the living body) metabolite consumption. It’s not just a new drug; it’s a new way to deliver therapy. While the synthetic biology space has many players, Synlogic, Inc.'s specific focus on engineered microbes for metabolic disease treatment using this reproducible, proprietary approach sets them apart from general synthetic biology platforms.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier to Entry\u003c\/h3\u003e\n\u003cp\u003eHonestly, this is tough to copy quickly. Imitation requires overcoming significant hurdles: massive initial research and development investment, and a deep, specialized bench of talent spanning both synthetic biology and gastroenterology. For the first three quarters of fiscal 2025, Synlogic, Inc. reported a cumulative net loss of USD 2.51 Million, indicating sustained investment into this platform, which narrows significantly from the USD -22.65 Million loss in the prior year period. Their total operating expenses for Q3 2025 were USD 0.99 Million. This level of sustained, specialized spending creates a moat.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Platform-Centric Structure\u003c\/h3\u003e\n\u003cp\u003eThe company is defintely organized around this technology. Every major asset in their pipeline - from SYNB1934 to SYNB2081 for gout - is a direct output of this synthetic biotic platform. Their collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for inflammatory bowel disease also centers on leveraging this core capability. This alignment means resources are focused on platform refinement and pipeline progression, which is exactly what you want to see.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how this platform stacks up against the VRIO criteria:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eCompetitive Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity or Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (Costly to Imitate)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Exploited)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk associated with clinical trial outcomes, but structurally, the platform itself is sound.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCreates oral, GI-restricted medicines.\u003c\/li\u003e\n\u003cli\u003eUses precision genetic engineering.\u003c\/li\u003e\n\u003cli\u003ePipeline includes Phase III asset (SYNB1934).\u003c\/li\u003e\n\u003cli\u003eCumulative 9M 2025 Net Loss: \u003cstrong\u003eUSD 2.51 Million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\nFinance: draft 13-week cash view by Friday.\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e2. Late-Stage Clinical Asset: SYNB1934 (PKU)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe status of SYNB1934 (labafenogene marselecobac) is defined by the discontinuation of its global, pivotal Phase 3 study, Synpheny-3, announced in February 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Synpheny-3 trial was discontinued after an internal review indicated the study was unlikely to meet its primary efficacy endpoint.\u003c\/li\u003e\n\u003cli\u003ePrior Phase 2 data for SYNB1934 demonstrated a 40% decrease in fasting plasma Phenylalanine (Phe) (95% CI: -52, -24).\u003c\/li\u003e\n\u003cli\u003eThe drug was designed to consume Phe in the GI tract, potentially offering a treatment as both monotherapy and adjunctive medical treatment.\u003c\/li\u003e\n\u003cli\u003eThe decision to halt the trial was \u003cstrong\u003enot\u003c\/strong\u003e based on safety concerns; the treatment was found to be safe and well-tolerated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSynlogic was leading the way in understanding how synthetic biotics could treat inherited metabolic disease, with no other approved synthetic biotics existing.\u003c\/li\u003e\n\u003cli\u003eThe Synpheny-3 trial was designed as a global, pivotal, multi-centre, randomized, placebo-controlled study.\u003c\/li\u003e\n\u003cli\u003eThe trial planned to enroll up to 150 patients aged 18 years and older with baseline plasma Phe levels of \u0026gt;360μM.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe clinical data package resulting in the trial discontinuation is unique to the Synpheny-3 execution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company's organization was heavily prioritized around this program, evidenced by the following financial and structural data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003e90% cut\u003c\/td\u003e\n\u003ctd\u003eFollowing trial discontinuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Halt Cash Runway Expectation\u003c\/td\u003e\n\u003ctd\u003eInto the second half of 2024\u003c\/td\u003e\n\u003ctd\u003eBased on March 31, 2023 balance sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Workforce Reduction\u003c\/td\u003e\n\u003ctd\u003e21% reduction\u003c\/td\u003e\n\u003ctd\u003eIn June (prior to Phase 3 initiation)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The failure of the pivotal trial nullified any immediate market advantage, leading the Board of Directors to evaluate strategic options including acquisition, merger, or dissolution.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e3. Regulatory Designations for Lead Asset\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe regulatory landscape surrounding Synlogic's lead asset, labafenogene marselecobac (previously \u003cstrong\u003eSYNB1934\u003c\/strong\u003e) for Phenylketonuria (PKU), provides significant, quantifiable value and competitive insulation.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe asset has secured multiple critical designations from major regulatory bodies, streamlining development and offering substantial market protection incentives.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA designations secured include \u003cstrong\u003eRare Pediatric Disease Designation (RPDD)\u003c\/strong\u003e, \u003cstrong\u003eFast Track\u003c\/strong\u003e, and \u003cstrong\u003eOrphan Drug Designation (ODD)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEMA designation includes \u003cstrong\u003eOrphan Designation\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eODD grants potential \u003cstrong\u003eseven years\u003c\/strong\u003e of market exclusivity in the U.S. post-approval.\u003c\/li\u003e\n\u003cli\u003eEMA Orphan Designation grants \u003cstrong\u003eten years\u003c\/strong\u003e of market exclusivity, extendable to \u003cstrong\u003e12 years\u003c\/strong\u003e upon compliance with an agreed paediatric investigation plan (PIP).\u003c\/li\u003e\n\u003cli\u003eRPDD provides the potential entitlement to a \u003cstrong\u003epediatric priority review voucher (pPRV)\u003c\/strong\u003e if initially approved for the rare childhood disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe achievement of this specific combination of high-value designations for a novel modality targeting PKU is uncommon.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePKU is classified as a rare disease, affecting \u003cstrong\u003efewer than 200,000 individuals in the U.S.\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe EMA Orphan Designation criteria is met if prevalence is below \u003cstrong\u003e5 in 10,000 EU inhabitants\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eCompetitors face a significant hurdle as these designations are tied to the specific drug-disease combination and the first-to-file\/first-to-market principle for exclusivity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDesignation Type\u003c\/td\u003e\n\u003ctd\u003eExclusivity Duration (Initial)\u003c\/td\u003e\n\u003ctd\u003eCondition for Competitor Entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA ODD\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7 years\u003c\/strong\u003e (U.S.)\u003c\/td\u003e\n\u003ctd\u003eSubsequent manufacturer must demonstrate \u003cstrong\u003eclinical superiority\u003c\/strong\u003e after exclusivity expires.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMA Orphan\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 years\u003c\/strong\u003e (EU)\u003c\/td\u003e\n\u003ctd\u003eCompetitors cannot market a \u003cstrong\u003esimilar medicine with similar indications\u003c\/strong\u003e during this period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe successful navigation of complex regulatory pathways to secure these designations demonstrates effective internal capability.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe clinical and regulatory teams successfully secured RPDD, ODD, and Fast Track from the FDA, and Orphan Designation from the EMA for SYNB1934.\u003c\/li\u003e\n\u003cli\u003eFast Track benefits include opportunities for \u003cstrong\u003efrequent meetings with the FDA\u003c\/strong\u003e and the ability to submit a registrational filing on a \u003cstrong\u003erolling basis\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe regulatory status confers a \u003cstrong\u003eSustained\u003c\/strong\u003e competitive advantage based on legally protected market exclusivity periods.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe combination of \u003cstrong\u003e7 years\u003c\/strong\u003e (FDA) and \u003cstrong\u003e10-12 years\u003c\/strong\u003e (EMA) of market exclusivity provides a substantial time-based barrier to entry for direct competitors targeting the same indication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e4. Strategic Collaboration with Roche (IBD)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe collaboration with Roche focuses on the research and pre-clinical development of a Synthetic Biotic medicine for the treatment of Inflammatory Bowel Disease (IBD).\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eRealization of value is evidenced by the achievement of research milestones, including the third such milestone, which resulted in a $2.5 million payment from Roche in November 2023. The collaboration structure includes potential future revenue streams via an exclusive option for Roche to enter a licensing and collaboration agreement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAchieved third research milestone, earning $2.5 million.\u003c\/li\u003e\n\u003cli\u003eRevenue for the three months ended September 30, 2023, was $0.4 million, primarily from the Roche collaboration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe partnership involves a major pharmaceutical entity, Roche, focusing on Synlogic's novel Synthetic Biotic platform for IBD, representing a significant market validation event.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe specific terms, including the undisclosed novel target in IBD and the exclusive option granted to Roche, create barriers to direct imitation of this specific arrangement.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe organization has demonstrated capability in executing the research plan, evidenced by the successful achievement of specified criteria leading to financial compensation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCollaboration Component\u003c\/th\u003e\n\u003cth\u003eInitial Financial\/Structural Term\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Access Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch Milestone Payments (Total Potential)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$5.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone Payments Received (as of Nov 2023)\u003c\/td\u003e\n\u003ctd\u003eThird payment of \u003cstrong\u003e$2.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Research Option\u003c\/td\u003e\n\u003ctd\u003eExclusive option for licensing and commercialization by Roche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe advantage is contingent upon the ongoing active status of the research collaboration and the successful progression toward Roche exercising its exclusive option.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e5. Collaboration with Ginkgo Bioworks\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe collaboration between Synlogic and Ginkgo Bioworks, formed in \u003cstrong\u003e2019\u003c\/strong\u003e, involves significant financial and resource commitments designed to accelerate the Synthetic Biotic medicine pipeline.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Access to an established, large-scale cell programming platform, accelerating strain development and optimization without massive internal capital expenditure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While many use platform services, Synlogic’s long-term, integrated use of a major synthetic biology partner is a specific resource arrangement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can contract with Ginkgo Bioworks, but Synlogic has established history and potentially optimized workflows with them.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This partnership was structured to accelerate preclinical leads into optimized drug candidates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It is an outsourced capability that can be replicated by others paying for similar services.\u003c\/p\u003e\n\n\u003cp\u003eThe core financial and structural elements of the initial agreement are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Collaboration Term\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFive year\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrategic platform collaboration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Collaboration Value (Services)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrepayment by Synlogic for foundry services over the initial term.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGinkgo Equity Investment in SYBX\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEquity investment at a premium.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYBX Shares Acquired by Ginkgo (Initial)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6,340,771\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003ctd\u003eIssued at \u003cstrong\u003e$9.00\u003c\/strong\u003e per share.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrants Issued to Ginkgo (Initial)\u003c\/td\u003e\n\u003ctd\u003eWarrants for \u003cstrong\u003e2.5 million\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003ctd\u003eExercise price of \u003cstrong\u003e$9.00\u003c\/strong\u003e per share.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Programs Contributed (as of Nov 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTwo\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrograms developed through the Ginkgo collaboration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime to Advance SYNB1353 to Candidate Strain\u003c\/td\u003e\n\u003ctd\u003eSpace of \u003cstrong\u003ea year\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAccelerated by Ginkgo's high-throughput testing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe collaboration has yielded specific clinical pipeline progress:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe first product developed from the partnership, SYNB1353 (for Homocystinuria), advanced to \u003cstrong\u003eIND-enabling studies\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSYNB1353 was designed using Ginkgo's proprietary codebase and \u003cem\u003eE. coli Nissle (EcN)\u003c\/em\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e6. GI-Restricted Oral Dosing Modality\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe modality is characterized by oral administration and non-systemic absorption, as seen with investigational candidates like labafenogene marselecobac (SYNB1934) for Phenylketonuria (PKU) and SYNB1353 for Homocystinuria (HCU).\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSYNB1934 is designed to reduce Phenylalanine (Phe) levels by consuming Phe in the gastrointestinal (GI) tract.\u003c\/li\u003e\n\u003cli\u003eSYNB1353 is designed to consume methionine in the GI tract.\u003c\/li\u003e\n\u003cli\u003eThe Synpheny-3 pivotal Phase 3 study for PKU expects to enroll approximately \u003cstrong\u003e150 patients\u003c\/strong\u003e with plasma Phe levels at baseline of \u003cstrong\u003e\u0026gt;360 μM\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe specialized nature of engineering bacteria for reliable, non-systemic action within the GI tract is evidenced by the platform's unique product class.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Candidate\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eGI-Restricted Mechanism\u003c\/th\u003e\n\u003cth\u003eRegulatory Designation (FDA)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabafenogene marselecobac (SYNB1934)\u003c\/td\u003e\n\u003ctd\u003ePKU\u003c\/td\u003e\n\u003ctd\u003eConsuming Phenylalanine (Phe) in the GI tract.\u003c\/td\u003e\n\u003ctd\u003eRare Pediatric Disease Designation, Fast Track designation, Orphan Drug Designation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1353\u003c\/td\u003e\n\u003ctd\u003eHCU\u003c\/td\u003e\n\u003ctd\u003eConsuming methionine in the gastrointestinal tract.\u003c\/td\u003e\n\u003ctd\u003eNot explicitly listed for SYNB1353 in recent summaries.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe technical achievement requires deep expertise, reflected in the development of candidates that have achieved significant regulatory milestones.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLabafenogene marselecobac (SYNB1934) received Orphan Designation from the European Medicines Agency (EMA).\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e were \u003cstrong\u003e$2.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe entire Synthetic Biotic platform is designed around this core principle of local action for multiple indications.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdditional product candidates address diseases including Homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, Synlogic had cash and cash equivalents of \u003cstrong\u003e$19.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThis is a fundamental, hard-won technical feature of their product class, suggesting a sustained advantage based on platform capability.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e7. Pipeline Breadth in Metabolic Diseases\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe pipeline demonstrates platform versatility by extending beyond the lead Phenylketonuria (PKU) program to address multiple distinct metabolic disorders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The platform's application spans several inborn errors of metabolism (IEMs) and related metabolic conditions, including PKU, Homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria, indicating a broad potential patient population addressable by the core technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The focused depth in IEMs, utilizing a single core technology (Synthetic Biotics) across multiple, distinct targets (e.g., Methionine\/Homocysteine for HCU, Oxalate for Enteric Hyperoxaluria, Uric Acid for Gout), represents a specialized and concentrated asset portfolio within the broader biotech landscape.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors may possess the capability to target a single metabolic pathway or disease; however, replicating the entire portfolio of validated metabolic targets, each requiring specific strain engineering and preclinical\/clinical de-risking, is resource-intensive and time-consuming.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company has articulated a clear strategy to address a spectrum of diseases where GI metabolite control is the key therapeutic mechanism, evidenced by the progression of multiple candidates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eTemporary.\u003c\/strong\u003e The advantage is contingent on successful clinical progression; pipeline asset failures, such as the discontinuation of the PKU program (Synpheny-3 study) in February 2024, can rapidly erode the perceived breadth and value.\u003c\/p\u003e\n\u003cp\u003eThe pipeline breadth across metabolic diseases is detailed below, reflecting the status as of recent corporate updates:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eProduct Candidate\u003c\/th\u003e\n\u003cth\u003eDevelopment Stage\/Key Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenylketonuria (PKU)\u003c\/td\u003e\n\u003ctd\u003elabafenogene marselecobac (SYNB1934)\u003c\/td\u003e\n\u003ctd\u003eDiscontinued pivotal Phase 3 study (Synpheny-3) in February 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClassical Homocystinuria (HCU)\u003c\/td\u003e\n\u003ctd\u003eSYNB1353\u003c\/td\u003e\n\u003ctd\u003eAchieved proof of mechanism in Phase 1 study; advancement to Phase 2 study previously planned.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnteric Hyperoxaluria\u003c\/td\u003e\n\u003ctd\u003eSYNB8802\u003c\/td\u003e\n\u003ctd\u003eDemonstrated proof of concept via positive lowering of urinary oxalate in a Phase 1b study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGout\u003c\/td\u003e\n\u003ctd\u003eSYNB2081\u003c\/td\u003e\n\u003ctd\u003eSecond drug candidate to advance to clinical development; designed to lower uric acid.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCystinuria\u003c\/td\u003e\n\u003ctd\u003eUndisclosed\u003c\/td\u003e\n\u003ctd\u003eExploring potential Synthetic Biotic approach.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial data supporting the ongoing development and strategic evaluation includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2024: \u003cstrong\u003e$19.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of June 30, 2024: \u003cstrong\u003e$20.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2024: A benefit of \u003cstrong\u003e$0.7 million\u003c\/strong\u003e (compared to expenses of \u003cstrong\u003e$9.6 million\u003c\/strong\u003e in Q3 2023), reflecting a reversal of accruals due to the discontinuation of Synpheny-3.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e8. Clinical Proof-of-Concept Data\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Early trial data validates the core mechanism of action - the engineered bacteria work as designed in humans.\u003c\/p\u003e\n\u003cp\u003eThe core mechanism of action has been validated through clinical studies demonstrating the intended metabolic effect in human subjects across multiple programs.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eKey Clinical Proof-of-Concept Data Point\u003c\/th\u003e\n\u003cth\u003eStudy Phase\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1618\/SYNB1934\u003c\/td\u003e\n\u003ctd\u003ePhenylketonuria (PKU)\u003c\/td\u003e\n\u003ctd\u003eDemonstrated \u003cstrong\u003eclinically meaningful reductions\u003c\/strong\u003e of plasma phenylalanine (Phe) levels.\u003c\/td\u003e\n\u003ctd\u003eInterim analysis of Phase 2 SynPheny-1 Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1934\u003c\/td\u003e\n\u003ctd\u003ePKU\u003c\/td\u003e\n\u003ctd\u003eDemonstrated \u003cstrong\u003etwo-fold increase\u003c\/strong\u003e in biomarkers of Phe metabolism compared to SYNB1618.\u003c\/td\u003e\n\u003ctd\u003eHead-to-head Phase 1 study in healthy volunteers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1353\u003c\/td\u003e\n\u003ctd\u003eHomocystinuria (HCU)\u003c\/td\u003e\n\u003ctd\u003eDemonstrated proof of mechanism by \u003cstrong\u003elowering plasma Met levels\u003c\/strong\u003e following methionine consumption in the GI tract.\u003c\/td\u003e\n\u003ctd\u003ePhase 1 clinical study data presentation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB8802\u003c\/td\u003e\n\u003ctd\u003eEnteric Hyperoxaluria\u003c\/td\u003e\n\u003ctd\u003eDemonstrated \u003cstrong\u003elowering of urinary and fecal oxalate levels\u003c\/strong\u003e in healthy volunteers with diet-induced hyperoxaluria.\u003c\/td\u003e\n\u003ctd\u003ePhase 1b study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Being the first company to reach certain milestones for this class of therapy is a significant differentiator.\u003c\/p\u003e\n\u003cp\u003eThe generation of human clinical data for Synthetic Biotic medicines in rare metabolic diseases represents a significant early mover advantage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReceived \u003cstrong\u003eRare Pediatric Disease Designation (RPDD)\u003c\/strong\u003e from the FDA for SYNB1934 for PKU.\u003c\/li\u003e\n\u003cli\u003eReceived \u003cstrong\u003eOrphan Drug Designation (ODD)\u003c\/strong\u003e from the FDA and a positive opinion on orphan designation from the EMA for SYNB1934.\u003c\/li\u003e\n\u003cli\u003eReceived \u003cstrong\u003eFast Track Designation\u003c\/strong\u003e from the FDA for SYNB1934.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors cannot replicate the actual human data Synlogic has already generated.\u003c\/p\u003e\n\u003cp\u003eThe specific quantitative and qualitative results from human trials are historical facts unique to Synlogic's platform and development efforts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003etwo-fold increase in Phe metabolism biomarkers\u003c\/strong\u003e observed with SYNB1934 versus SYNB1618 is proprietary clinical evidence.\u003c\/li\u003e\n\u003cli\u003eThe data showing \u003cstrong\u003elowering of plasma Met levels\u003c\/strong\u003e in HCU patients from the Phase 1 study cannot be replicated by competitors without running similar trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company effectively presented positive Phase 1\/2 data at scientific meetings.\u003c\/p\u003e\n\u003cp\u003eSynlogic has presented its clinical findings at key scientific forums, demonstrating organizational capability in data generation and dissemination.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnnounced full data from both the Phase 2 Synpheny-1 study in PKU and the Phase 1 study in HCU at the \u003cstrong\u003eSociety for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePositive results from the Synpheny-1 Phase 2 study were also presented at the \u003cstrong\u003e37th E.S. PKU Conference 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData showing increased methionine degradation activity by SYNB1353 were presented at the \u003cstrong\u003eInternational Conference on Microbiome Engineering 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Past clinical results are historical facts that cannot be undone or easily matched by new entrants.\u003c\/p\u003e\n\u003cp\u003eThe established clinical proof-of-concept provides a sustained advantage, even as the company adjusted its development plans, such as discontinuing the Synpheny-3 study in February 2024. The historical data remains a barrier to entry.\u003c\/p\u003e\n\u003cp\u003eFinancial context related to pipeline progress includes earning a \u003cstrong\u003e$2.5 million\u003c\/strong\u003e milestone payment from the Roche collaboration in November 2023. As of \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e, cash and cash equivalents were \u003cstrong\u003e$20.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynlogic, Inc. (SYBX) - VRIO Analysis: \u003cstrong\u003e9. Demonstrated Efficacy Metrics\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Early human data showed a \u003cstrong\u003e25 to 40 percent\u003c\/strong\u003e reduction in target metabolite concentration across three disease applications in Phase 1 and Phase 2 trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Quantifiable, double-digit efficacy in early human trials for a first-in-class therapy is rare and highly valuable for investor confidence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific magnitude of effect achieved in their trials is unique to their engineered strains.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This data underpins the confidence to push SYNB1934 into a pivotal Phase 3 study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is a hard-won, validated performance metric for their technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: Sensitivity Analysis on Cash Runway Extension based on Potential Q1 2026 Phase 3 Data Readout\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe latest reported cash and cash equivalents for Synlogic, Inc. as of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, was \u003cstrong\u003e$19.4 million\u003c\/strong\u003e. The net loss for the third quarter of 2024 was \u003cstrong\u003e$(0.1) million\u003c\/strong\u003e, though this figure included a benefit from accrual reversals related to the discontinuation of the Synpheny-3 study. For the three months ended June 30, 2024, the company reported a net income of \u003cstrong\u003e$2.0 million\u003c\/strong\u003e, which was due to a gain on restructuring charges of \u003cstrong\u003e$3.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe following table illustrates a hypothetical sensitivity analysis for the cash runway extension, assuming the \u003cstrong\u003e$19.4 million\u003c\/strong\u003e cash balance is the starting point immediately following a Q1 2026 data readout, based on different assumed post-readout quarterly net losses (cash burn rates). The runway is calculated in quarters from that point forward.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eScenario\u003c\/td\u003e\n\u003ctd\u003eAssumed Quarterly Net Loss (USD)\u003c\/td\u003e\n\u003ctd\u003eCash Runway (Quarters)\u003c\/td\u003e\n\u003ctd\u003eCash Runway (Months)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest Case (Cost Containment)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(0.5) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e116.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBaseline (Q3 2024 Normalized OpEx Proxy)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(3.4) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModerate Burn (Pre-Restructuring OpEx Proxy)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(5.0) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggressive Burn (Increased R\u0026amp;D\/G\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(7.0) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe baseline quarterly operating expenses for Q3 2024, excluding the restructuring benefit\/reversal, were approximately \u003cstrong\u003e$3.4 million\u003c\/strong\u003e (R\u0026amp;D of \u003cstrong\u003e$2.2 million\u003c\/strong\u003e plus G\u0026amp;A of \u003cstrong\u003e$1.2 million\u003c\/strong\u003e). The company's Q3 2024 net loss was \u003cstrong\u003e$(0.1) million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe cash runway extension is highly sensitive to the post-readout operational expenditure and any potential financing or partnership milestones achieved following the data release. Key components influencing the actual burn rate include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses, which were \u003cstrong\u003e$2.2 million\u003c\/strong\u003e for the three months ended June 30, 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses, which were \u003cstrong\u003e$1.2 million\u003c\/strong\u003e for the three months ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe potential for a significant milestone payment from the Roche collaboration, which previously provided \u003cstrong\u003e$0.4 million\u003c\/strong\u003e in revenue for Q3 2023.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516259852437,"sku":"sybx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sybx-vrio-analysis.png?v=1740219662","url":"https:\/\/dcf-model.com\/fr\/products\/sybx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}